Lonapegsomatropin
Names | |
---|---|
Trade names | Skytrofa |
Other names | Lonapegsomatropin-tcgd; Lonapegsomatropin Ascendis Pharma; rhGH-PEG; ACP-011; ΤransConPEG hGh; WHO-10598 |
Clinical data | |
Drug class | Growth hormone receptor agonist |
Main uses | Growth hormone deficiency[1] |
Side effects | Headache, joint pain, low thyroid, pain at the site of injection[2] |
Routes of use | Subcutaneous injection |
Legal | |
License data | |
Legal status | |
Chemical and physical data | |
Formula | C1051H1627N269O317S9[C2H4O]4n |
Lonapegsomatropin, sold under the brand name Skytrofa, is a medication used to treat growth hormone deficiency.[1] It may be used in children from the ages of 1 to 18 year.[1][2] It is given by injection under the skin once per week.[2]
Common side effects include headache, joint pain, low thyroid, and pain at the site of injection.[2] Other side effects may include allergic reactions, cancer, diabetes, intracranial hypertension, swelling, pancreatitis, and slipped capital femoral epiphysis.[1] It is a human growth hormone (somatropin) that has been developed to be long acting.[1][2]
Lonapegsomatropin was approved for medical use in the United States in 2021 and Europe in 2022.[1][2] In the United States it costs 2,800 to 12,300 USD per week, depending on the weight of the child.[4] As of 2022 it is not yet commercial available in Europe.[5]
Medical uses
Lonapegsomatropin is a growth hormone therapy indicated to treat growth hormone deficiency.[1][2] It is equivalent to somatropin but only needs to be given once per week.[2]
Dosage
The typical dose is 0.24 mg/kg by injection once per week.[1]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 "Skytrofa- lonapegsomatropin-tcgd injection, powder, lyophilized, for solution". DailyMed. Archived from the original on 1 October 2021. Retrieved 30 September 2021.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 "Lonapegsomatropin Ascendis Pharma EPAR". European Medicines Agency. 10 November 2021. Archived from the original on 16 March 2022. Retrieved 16 March 2022.
- ↑ "Skytrofa: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 26 August 2021. Retrieved 25 August 2021.
- ↑ "Skytrofa Prices, Coupons, Copay & Patient Assistance". Drugs.com. Retrieved 27 October 2022.
- ↑ "Lonapegsomatropin". SPS - Specialist Pharmacy Service. 7 March 2019. Archived from the original on 17 January 2022. Retrieved 27 October 2022.
Further reading
- Thornton PS, Maniatis AK, Aghajanova E, Chertok E, Vlachopapadopoulou E, Lin Z, et al. (July 2021). "Weekly Lonapegsomatropin in Treatment-Naïve Children with Growth Hormone Deficiency: The Phase 3 heiGHt Trial". The Journal of Clinical Endocrinology and Metabolism. 106 (11): 3184–3195. doi:10.1210/clinem/dgab529. PMC 8530727. PMID 34272849.
External links
External sites: | |
---|---|
Identifiers: |
- Clinical trial number NCT02781727 for "A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)" at ClinicalTrials.gov
- Pages using duplicate arguments in template calls
- Use American English from August 2021
- Articles with invalid date parameter in template
- All Wikipedia articles written in American English
- Use dmy dates from August 2021
- Drugs with non-standard legal status
- Infobox drug articles without a structure image
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Drugs not assigned an ATC code
- Growth hormones
- Orphan drugs
- All stub articles
- Systemic hormonal preparation stubs